Addition of ETA receptor blockade increases renoprotection provided by renin–angiotensin system blockade in 5/6 nephrectomized Ren-2 transgenic rats

Life Sciences

Volumn 118, Issue 2, 2014, Pages 297-305

  Čertíková Chábová, Věra ^a   Vernerová, Zdenka ^a   Kujal, Petr ^a   Husková, Zuzana ^b   Škaroupková, Petra ^b   Tesař, Vladimír ^a   Kramer, Herbert J ^c   Kompanowska Jezierska, Elzbieta ^d   Walkowska, Agnieszka ^d   Sadowski, Janusz ^d   Červenka, Luděk ^b   Vaněčková, Ivana ^e  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c UNIVERSITY OF BONN   (Germany)

^d MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^e INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

5 6 nephrectomy; Chronic kidney disease; End organ damage; Endothelin receptor type A; Hypertension

Indexed keywords

ANGIOTENSIN; ATRASENTAN; ENDOTHELIN A RECEPTOR; LOSARTAN; RENIN; TRANDOLAPRIL; ANGIOTENSIN II; ENDOTHELIN 1; ENDOTHELIN RECEPTOR ANTAGONIST; PROTECTIVE AGENT; REN2 PROTEIN, RAT;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FOLLOW UP; HYPERTENSION; MALE; NEPHRECTOMY; NONHUMAN; PROTEINURIA; RAT; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STANDARD; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; TRANSGENIC RAT; ANIMAL; BLOOD; BLOOD PRESSURE; CARDIOMEGALY; COMPLICATION; DRUG EFFECTS; GENETICS; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; SYSTOLE;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; CARDIOMEGALY; ENDOTHELIN RECEPTOR ANTAGONISTS; ENDOTHELIN-1; KIDNEY; KIDNEY DISEASES; NEPHRECTOMY; PROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RATS, TRANSGENIC; RECEPTOR, ENDOTHELIN A; RENIN; RENIN-ANGIOTENSIN SYSTEM; SYSTOLE;

EID: 84891705751     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2013.12.018     Document Type: Article

References (47)

1. A receptors for endothelin regulation. Biochem Biophys Res Commun 238 (1997), 861–865.
2. Benigni, A., Zoja, C., Corna, D., Orisio, S., Langaretti, L., Bertani, T., et al. A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney Int 44 (1993), 440–444.
3. A activation mediates angiotensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol 22 (2011), 2187–2192.
4. Brenner, B.M., Nephron adaptation to renal injury or ablation. Am J Physiol 249 (1985), F324–F337.
5. Briet, M., Burns, K.D., Chronic kidney disease and vascular remodeling: molecular mechanisms and clinical implications. Clin Sci 123 (2012), 399–416.
6. A receptor blockade prevents the progression of renal failure and hypertension in uraemic rats. Nephrol Dial Transplant 14 (1999), 1881–1888.
7. Cao, Z., Cooper, M.E., Wu, L.L., Cox, A.J., Jandeleit-Dahm, K., Kelly, D.J., et al. Blockade of the renin–angiotensin and endothelin systems on progressive renal injury. Hypertension 36 (2000), 561–568.
8. Čertíková Chábová, V., Walkowska, A., Kompanowska-Jezierska, E., Sadowski, J., Kujal, P., Verenrová, Z., et al. Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and epoxyeicosatrienoic acids degradation attenuates hypertension and hypertension-induced end-organ damage in Ren-2 transgenic rats. Clin Sci 118 (2010), 617–632.
9. 1A receptor knockout mice. J Hypertens 26 (2008), 1379–1389.
10. Fujihara, C.K., Velho, M., Malheiros, D.M., Zatz, R., An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int 67 (2005), 1913–1924.
11. Gonzalez-Villalobos, R.A., Janjoulia, T., Fletcher, N.K., Giani, J.F., Nguyen, M.T.X., Riquier-Brison, A.D., et al. The absence of intrarenal ACE protects against hypertension. J Clin Invest 125 (2013), 2011–2023.
12. Gordon, J., Kopp, J.B., Off the beaten renin–angiotensin–aldosterone system pathway: new perspectives on antiproteinuric therapy. Adv Chronic Kidney Dis 18 (2011), 300–311.
13. Honetschlagerová, Z., Kitada, K., Husková, Z., Sporková, A., Kopkan, L., Bürgelová, M., et al. Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens 31 (2013), 321–332.
14. Hostetter, T.H., Hyperfiltration and glomerulosclerosis. Semin Nephrol 23 (2003), 194–199.
15. Huskova, Z., Kramer, H.J., Thumova, M., Vanourkova, Z., Burgelova, M., Teplan, V., et al. Effects of anesthesia on plasma and kidney ANG II levels in normotensive and ANG II-dependent hypertensive rats. Kidney Blood Press Res 29 (2006), 74–83.
16. Husková, Z., Vaňourková, Z., Erbanová, M., Thumová, M., Opočenský, M., Mullins, J.J., et al. Inappropriately high circulating and intrarenal angiotensin II levels during dietary salt loading exacerbate hypertension in Cyp1a1-Ren-2 transgenic rats. J Hypertens 28 (2010), 495–509.
17. Kang, C.S., Chan, N.C., Chan, S.T., Lin, C.C., Lee, T.M., Effect of pravastatin on nephroprotection in deoxycosterone acetate-salt hypertensive rats. J Hypertens 27 (2009), 2232–2243.
18. Ketteler, M., Noble, N.A., Border, W.A., Transforming growth factor-β and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?. Annu Rev Physiol 57 (1995), 279–295.
19. Kobori, H., Nangaku, M., Navar, L.G., Nishiyama, A., The intrarenal renin–angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 59 (2007), 251–287.
20. Kohan, D.E., Endothelin, hypertension and chronic kidney disease: new insight. Curr Opin Nephrol Hypertens 19 (2010), 134–139.
21. Kohan, D.E., Rossi, N.F., Inscho, E.W., Pollock, D.M., Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 91 (2011), 1–77.
22. Kujal, P., Certíková Chábová, V., Vernerova, Z., Walkowska, A., Kompanowska-Jezierska, E., Sadowski, J., et al. Similar renoprotection after renin–angiotensin-dependent and -independent antihypertensive therapy in 5/6-nephrectomized Ren-2 transgenic rats: are there blood pressure-independent effects?. Clin Exp Pharmacol Physiol 37 (2010), 1159–1169.
23. Kurtz, T.W., Griffin, K.A., Bidani, A.K., Davisson, R.L., Hall, J.E., Recommendations for blood pressure measurements in humans and experimental animals. Part 2: blood pressure measurements in experimental animals. Hypertension 45 (2005), 299–310.
24. Lane, P.H., Steffes, M.W., Mauer, M.S., Estimation of glomerular volume: a comparison of four methods. Kidney Int 41 (1992), 1085–1089.
25. Macconi, D., Targeting the renin angiotensin system for remission/regression of chronic kidney disease. Histol Histopathol 25 (2010), 655–668.
26. Mancia, G., De Backer, G., Dominiczak, A., Cifkova, R., Fagard, R., Germano, G., et al. Guidelines for the Management of Arterial Hypertension. The task force of the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007), 1105–1187.
27. Mullins, J.J., Peters, J., Ganten, D., Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 344 (1990), 541–544.
28. Perico, N., Amuchastegui, S.C., Colosio, V., Sonzogni, G., Bertani, T., Remuzzi, G., Evidence that an angiotensin-converting enzyme inhibitor has a different effect on glomerular injury according to the different phase of the disease at which the treatment is started. J Am Soc Nephrol 5 (1994), 1139–1146.
29. A receptor blockade prevents hypertension associated with exogenous endothelin-1 but not renal mass reduction in the rat. J Am Soc Nephrol 8 (1997), 1054–1060.
30. Potter, G.S., Johnson, R.J., Fink, G.D., Role of endothelin in hypertension of experimental chronic renal failure. Hypertension 30 (1997), 1578–1584.
31. Ptinopolou, A.G., Pikilidou, M.I., Lasaridis, N., The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review. Hypertens Res 36 (2013), 91–101.
32. Rossi, G.P., Sacchetto, A., Cesari, M., Pessina, A.C., Interactions between endothelin-1 and renin–angiotensin–aldosterone system. Cardiovasc Res 43 (1999), 300–307.
33. Rüster, C., Wolf, G., Renin–angiotensin–aldosterone system and progression of renal disease. J Am Soc Nephrol 17 (2006), 2985–2991.
34. Saito, T., Sumithran, E., Glasgow, E.F., Atkins, R.C., The enhancement of aminonucleoside nephrosis by the co-administration of protamine. Kidney Int 32:5 (1987), 691–699.
35. Sasser, J.M., Pollock, J.S., Pollock, D.M., Renal endothelin in chronic angiotensin II hypertension. Am J Physiol 283 (2002), R243–R248.
36. Turner, J.M., Bauer, C., Abramowitz, M.K., Melamed, M.L., Hostetter, T.H., Treatment of chronic kidney disease. Kidney Int 81 (2012), 351–362.
37. U.S. Renal Data System: USEDS, Annual data report: Atlas of chronic kidney disease and end-stage renal disease in the United States. 2012, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda MD 2012.
38. Upadhyay, A., Early, A., Hanyes, S.M., Uhlig, K., Systemic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med 154 (2011), 541–548.
39. Vaněčková, I., Kramer, H., Backer, A., Vernerová, Z., Opočenský, M., Červenka, L., Early endothelin-A receptor blockade decreases blood pressure and ameliorates end-organ damage in homozygous Ren-2 rats. Hypertension 46 (2005), 969–974.
40. Vaněčková, I., Kujal, P., Husková, Z., Vaňourková, Z., Vernerová, Z., Čertíková Chábová, V., et al. Effects of combined endothelin A receptor and renin–angiotensin system blockade on the course of end-organ damage in 5/6 nephrectomized Ren-2 hypertensive rats. Kidney Blood Press Res 35 (2012), 382–392.
41. Vaňourková, Z., Kramer, H.J., Husková, Z., Červenka, L., Vaněčková, I., Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res 59 (2010), 339–345.
42. Vernerová, Z., Kujal, P., Kramer, H.J., Backer, A., Červenka, L., Vaněčková, I., End-organ damage in hypertensive transgenic Ren-2 rats: influence of early and late endothelin receptor blockade. Physiol Res 58:Suppl. 2 (2009), S69–S78.
43. Wheeler, D.C., Becker, G.J., Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease?. Kidney Int 83 (2013), 377–383.
44. Yao, L., Kobori, H., Rahman, M., Seth, D.M., Shokoji, T., Fan, Y., et al. Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 27 (2004), 493–500.
45. Yoshida, Y., Fogo, A., Ichikawa, I., Glomerular hemodynamic changes vs. Hypertrophy in experimental glomerular sclerosis. Kidney Int 35 (1989), 654–660.
46. Yoshida, Y., Kawamura, T., Ikoma, M., Fogo, A., Ichikawa, I., Effects of antihypertensive drugs on glomerular morphology. Kidney Int 36 (1989), 626–635.
47. Zoja, C., Abbate, M., Remuzzi, G., Progression of chronic kidney disease: insight from animal models. Curr Opin Nephrol Hypertens 15 (2006), 250–257.